VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 366 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $48,000 | -65.0% | 3,339 | -40.0% | 0.02% | -64.7% |
| Q3 2016 | $137,000 | +140.4% | 5,567 | +95.5% | 0.07% | +134.5% |
| Q2 2016 | $57,000 | +62.9% | 2,848 | +115.3% | 0.03% | +45.0% |
| Q1 2016 | $35,000 | -69.0% | 1,323 | +18.7% | 0.02% | -67.7% |
| Q4 2015 | $113,000 | -28.9% | 1,115 | +25.3% | 0.06% | -34.7% |
| Q3 2015 | $159,000 | -26.7% | 890 | -8.7% | 0.10% | -26.9% |
| Q2 2015 | $217,000 | -10.3% | 975 | -20.1% | 0.13% | -15.6% |
| Q1 2015 | $242,000 | +38.3% | 1,220 | 0.0% | 0.15% | +35.1% |
| Q4 2014 | $175,000 | +9.4% | 1,220 | 0.0% | 0.11% | +6.5% |
| Q3 2014 | $160,000 | +3.9% | 1,220 | 0.0% | 0.11% | -4.5% |
| Q2 2014 | $154,000 | -4.3% | 1,220 | 0.0% | 0.11% | -6.7% |
| Q1 2014 | $161,000 | -43.7% | 1,220 | -50.0% | 0.12% | +12.1% |
| Q4 2013 | $286,000 | +72.3% | 2,440 | +53.0% | 0.11% | -20.1% |
| Q3 2013 | $166,000 | +21.2% | 1,595 | 0.0% | 0.13% | +14.5% |
| Q2 2013 | $137,000 | – | 1,595 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |